COCH Stock: Insider Activity, Filings & Research
Envoy Medical, Inc. (COCH) — Drillr’s hub for COCH insider activity, SEC filings, earnings signals and AI research.
COCH insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 4, 2026 | Lucas Brent T.director, officer: Chief Executive Officer | Grant | 32,856 | $0.60 |
| Apr 17, 2026 | McKhann Chasdirector | Grant | 100,000 | $0.72 |
| Feb 17, 2026 | Potashnick Robertofficer: Interim CFO | Buy | 127,500 | $0.40 |
| Feb 17, 2026 | Kantor Susandirector | Buy | 96,150 | $0.40 |
| Feb 17, 2026 | Kantor Susandirector | Buy | 57,690 | $0.40 |
| Feb 17, 2026 | BRYNELSEN CHARLESdirector | Buy | 1,000,000 | $0.40 |
| Feb 17, 2026 | BRYNELSEN CHARLESdirector | Buy | 600,000 | $0.40 |
| Feb 17, 2026 | Lucas Brent T.director, officer: Chief Executive Officer | Buy | 62,500 | $0.40 |
| Feb 17, 2026 | Lucas Brent T.director, officer: Chief Executive Officer | Buy | 37,500 | $0.40 |
| Feb 17, 2026 | TAYLOR GLEN A10 percent owner | Buy | 18,750,000 | $0.40 |
| Feb 17, 2026 | TAYLOR GLEN A10 percent owner | Buy | 11,250,000 | $0.40 |
| Feb 17, 2026 | Patel Mona Chetandirector | Buy | 312,500 | $0.40 |
| Feb 17, 2026 | Potashnick Robertofficer: Interim CFO | Buy | 212,500 | $0.40 |
| Feb 17, 2026 | Patel Mona Chetandirector | Buy | 187,500 | $0.40 |
| Feb 9, 2026 | Potashnick Robertofficer: Interim CFO | Grant | 15,000 | $0.53 |
Source: COCH SEC Form 4 filings, latest Jun 4, 2026. For informational purposes only — not investment advice.
Envoy Medical, Inc. company profile
Overview
Envoy Medical, Inc. (NASDAQ:COCH) is a hearing health company founded in 1995 and headquartered in White Bear Lake, Minnesota. Originally established as St. Croix Medical, Inc., the company changed its name to Envoy Medical Corporation in December 2004 before becoming Envoy Medical, Inc. The company went public in April 2021 and develops medical technologies designed to address various forms of hearing loss across the hearing loss spectrum.
Business
Envoy Medical operates in the medical device industry, specifically focusing on hearing health solutions. The company develops and manufactures implantable and non-implantable devices designed to treat different types and severities of hearing loss. The company's product portfolio includes four main categories of hearing solutions. Hearing aids represent traditional amplification devices that make sounds louder for people with mild to moderate hearing loss. Esteem middle ear implants are surgically implanted devices that work by directly driving the bones of the middle ear, providing a more natural hearing experience for patients with sensorineural hearing loss who cannot benefit adequately from hearing aids. Bone conduction devices transmit sound vibrations through the skull bone directly to the inner ear, bypassing damaged parts of the outer or middle ear. Acclaim cochlear implants are sophisticated electronic devices surgically implanted in the inner ear that directly stimulate the auditory nerve, providing a sense of sound to individuals with severe to profound hearing loss. The hearing loss treatment market operates on a spectrum from mild hearing loss (treated with hearing aids) to profound deafness (requiring cochlear implants). Envoy Medical's strategy involves offering solutions across this entire spectrum, allowing the company to serve patients with varying degrees of hearing impairment. The medical device industry for hearing solutions is highly regulated, requiring FDA approval for implantable devices and adherence to strict quality and safety standards.
Revenue model
Envoy Medical generates revenue primarily through the sale of medical devices to healthcare providers, hospitals, and hearing specialists. The company operates on a product sales business model where it manufactures and sells its hearing devices to medical professionals who then implant or fit them for patients. The company's revenue streams come from both one-time device sales and potentially recurring revenue from device maintenance, upgrades, and replacement components. Healthcare providers, ENT surgeons, audiologists, and specialized hearing clinics represent the primary customer base. Patients typically receive these devices through insurance coverage, Medicare, or direct payment, but Envoy Medical's direct customers are the medical professionals and institutions. Several factors significantly impact the company's margins and profitability. Regulatory approval processes create substantial upfront costs and time delays before products can generate revenue. Research and development expenses are considerable given the sophisticated nature of implantable medical devices. Manufacturing costs are influenced by the precision required for medical-grade components and small production volumes typical of specialized medical devices. Competition from established players like Cochlear Limited, MED-EL, and Advanced Bionics can pressure pricing and market share. Insurance reimbursement policies directly affect patient access and demand for these expensive devices. Clinical trial requirements and the need for long-term safety data create ongoing expenses that may not immediately translate to revenue.
Competitive moat
Envoy Medical operates in a challenging competitive environment with limited moat protection. The company's primary competitive advantages include its FDA-approved product portfolio and intellectual property around its device technologies, particularly the Esteem middle ear implant system. However, these advantages are relatively weak compared to established industry leaders. The hearing device industry is dominated by large, well-capitalized companies with extensive research and development capabilities, established distribution networks, and strong relationships with healthcare providers. Companies like Cochlear Limited, Sonova, and William Demant have significant scale advantages, broader product portfolios, and global market presence that Envoy Medical cannot match. The company faces substantial competitive threats from multiple directions. Technological disruption could come from advances in hearing aid technology that reduce the need for implantable devices, or from new entrants with superior technology. Established competitors have greater resources to invest in R&D, clinical trials, and market expansion. Regulatory barriers that protect the company also work against it, as larger competitors can more easily navigate complex approval processes. The company's small size and limited financial resources make it vulnerable to being outspent on innovation and marketing by larger competitors. Overall, Envoy Medical's moat appears weak, with the company operating more as a niche player in a market dominated by much larger, better-resourced competitors.
Risks & safety
Envoy Medical presents significant financial risk with a very narrow margin of safety. • Cash burn and solvency: The company burned $3.7 million in operating cash flow in Q1 2025, with only $5.3 million in cash remaining. At current burn rates, the company has approximately 4-6 quarters of runway before requiring additional financing. • Debt and liabilities: Total liabilities of $34.6 million significantly exceed total assets of $10.4 million, creating a negative book value of approximately $24.2 million. Current ratio of 1.09 indicates tight liquidity. • Valuation metrics: With minimal revenue ($46,000 in Q1 2025) and substantial losses ($5.0 million net loss in Q1 2025), traditional valuation metrics are not meaningful. The company trades at a market cap of approximately $32.5 million. • Revenue trajectory: Revenue has declined from $316,000 in 2023 to $225,000 in 2024, indicating deteriorating business fundamentals. • Other considerations: The company will likely need to raise capital soon, which could significantly dilute existing shareholders. The combination of cash burn, declining revenue, and massive liabilities creates substantial bankruptcy risk.
Recent development
Based on the available financial data, Envoy Medical appears to be in a challenging operational phase with declining revenue and increasing losses. The company's revenue dropped from $316,000 in 2023 to $225,000 in 2024, while maintaining high operating expenses typical of a medical device company engaged in research and development activities. The company's quarterly revenue has been inconsistent, ranging from $42,000 to $68,000 across recent quarters, suggesting challenges in commercializing its products or maintaining consistent sales momentum. The substantial net losses, exceeding $20 million annually, indicate the company is still in a pre-profitability stage despite being founded in 1995 and public since 2021. Without access to recent earnings call transcripts, specific strategic initiatives and product development updates are not available. However, the financial trajectory suggests the company may be facing significant operational challenges in bringing its hearing device technologies to market successfully or achieving meaningful commercial scale.
COCH company profile · for informational purposes only — not investment advice.
Track COCH with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free